@article{a6136225ccd646d987bceab218b98da7,
title = "Response to: Treatment of (Recurrent) Clostridioides difficile Infections in Children and Adults",
author = "Kociolek, {Larry K.} and Davidovics, {Zev H.} and Kahn, {Stacy A.} and Richard Kellermayer",
note = "Funding Information: Acknowledgments: External funding: This commentary was written without external funding. Conflicts of interest: E.J.K. and M.J.G.T.V. represent the ESCMID study group for host and microbiota interaction group (ESGHAMI), and J.E.C. represents the ESCMID study group of Clostridioides difficile. E.J.K. received research funding from Vedanta biosciences, Boston; J.E.C. has nothing to disclose; M.J.G.T.V. has served at the speakers{\textquoteright} bureau of Akademie f{\"u}r Infektionsmedizin, {\"A}rztekammer Nordrhein, Astellas Pharma, Basisgids, Gilead Sciences, Merck/ MSD, Organobalance and Pfizer, received research funding from 3M, Astellas Pharma, DaVolterra, Gilead Sciences, MaaT Pharma, Merck/MSD, Morphochem, Organobalance, Seres Therapeutics, Uniklinik Freiburg/Kongress und Kommunikation and is a consultant to Alb-Fils Kliniken GmbH, Arderypharm, Astellas Pharma, Berlin Chemie, DaVolterra, MaaT Pharma, and Merck/MSD; J.K. received research funding from Vedanta biosciences, Boston; L.T. has nothing to disclose.",
year = "2019",
doi = "10.1097/MPG.0000000000002388",
language = "English (US)",
volume = "69",
pages = "e58--e59",
journal = "Journal of Pediatric Gastroenterology and Nutrition",
issn = "0277-2116",
publisher = "Lippincott Williams and Wilkins",
number = "2",
}